Trial Profile
To evaluate the efficacy of XELOX+Bevacizumab for patient with Metastatic Colorectal Cancer as second-line chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 27 Jan 2021 Status changed from active, no longer recruiting to completed.
- 06 Feb 2012 New trial record